Baird Financial Group
RCKT icon

Baird Financial Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Baird Financial Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,661
Closed -$147K – 1812
2022
Q2 		$147K Buy
+10,661
New +$127K ﹤0.01% 1724

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Baird Financial Group's RCKT Position: Q3 2022 in Review

Baird Financial Group sold out of Rocket Pharmaceuticals (RCKT) in Q3 2022, closing a stake of 10,661 shares — an estimated $147K sold.

Baird Financial Group first reported a position in RCKT in Q2 2022 and held it in 1 quarter. The position peaked at $147K in Q2 2022. 164 funds tracked by Wall St. Rank hold RCKT as of Q3 2022.

  • Baird Financial Group reported no remaining Rocket Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Baird Financial Group sold 10,661 Rocket Pharmaceuticals shares in Q3 2022, an estimated $147K.
  • Baird Financial Group first reported a position in Rocket Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Baird Financial Group's Rocket Pharmaceuticals position peaked at $147K in Q2 2022.
  • 164 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2022.

Based on Baird Financial Group's 13F filing for Q3 2022, filed 15 Nov 2022.